The Sixteenth International Conference on Endothelin (ET-16), Kobe, 2019.

The Sixteenth International Conference on Endothelin (ET-16) was held September 22-25, 2019, in Kobe Port Oasis, Kobe, Japan, and co-chaired by Noriaki Emoto, MD, PhD, from Kobe Pharmaceutical University and Bambang Widyantoro, MD, PhD, from the University of Indonesia. As the sixteenth iteration of this biannual conference that has been held since 1988, ET-16 provided a platform for researchers of all generations from all parts of the world to present novel discoveries in the field of endothelin. ET-16 returned to Asia and to Kobe, Japan, after 6 years of alternating venues with North America and Europe, with over 100 participants attending, sharing, and discussing the newest findings on endothelin and endothelin receptor antagonists in science and medicine.

Endothelin: 30 Years From Discovery to Therapy.

Discovered in 1987 as a potent endothelial cell-derived vasoconstrictor peptide, endothelin-1 (ET-1), the predominant member of the endothelin peptide family, is now recognized as a multifunctional peptide with cytokine-like activity contributing to almost all aspects of physiology and cell function. More than 30 000 scientific articles on endothelin were published over the past 3 decades, leading to the development and subsequent regulatory approval of a new class of therapeutics-the endothelin receptor antagonists (ERAs). This article reviews the history of the discovery of endothelin and its role in genetics, physiology, and disease. Here, we summarize the main clinical trials using ERAs and discuss the role of endothelin in cardiovascular diseases such as arterial hypertension, preecclampsia, coronary atherosclerosis, myocardial infarction in the absence of obstructive coronary artery disease (MINOCA) caused by spontaneous coronary artery dissection (SCAD), Takotsubo syndrome, and heart failure. We also discuss how endothelins contributes to diabetic kidney disease and focal segmental glomerulosclerosis, pulmonary arterial hypertension, as well as cancer, immune disorders, and allograft rejection (which all involve ETA autoantibodies), and neurological diseases. The application of ERAs, dual endothelin receptor/angiotensin receptor antagonists (DARAs), selective ETB agonists, novel biologics such as receptor-targeting antibodies, or immunization against ETA receptors holds the potential to slow the progression or even reverse chronic noncommunicable diseases. Future clinical studies will show whether targeting endothelin receptors can prevent or reduce disability from disease and improve clinical outcome, quality of life, and survival in patients.

The Fourth Tomoh Masaki Award.

Doctor David J. Webb MD, DSc, FRCP, FRSE, FMedSci, a clinical pharmacologist specialising in the management of cardiovascular disease, is the recipient of The Fourth Tomoh Masaki Award, a bi-annual prize presented on the occasion of the International Conferences on Endothelin to scientists for outstanding contributions and achievements in the field of endothelin research. The Fourth Tomoh Masaki Award was presented to Doctor Webb at the Fifteenth International Conference on Endothelin which was held at Duo Hotel, Prague, Czech Republic, in October 2017. The award was granted to Dr. Webb during the Award Ceremony in Troja Chateau "In Recognition of his Outstanding Contributions to Science and Endothelin Research in Particular". This article summarises the career and the scientific achievements of David J. Webb viewed by his former student Dr. Neeraj Dhaun, known to everybody as 'Bean'.

Sidney George Shaw, DPhil (1948-2017).

On March 4, 2017 at the age of 68, Sidney George Shaw (Sid) unexpectedly died from complications following surgery, only four years after retiring from the University of Bern. Trained in biochemistry at Oxford University, Sid had quickly moved into molecular pharmacology and became a key investigator in the field of enzyme biochemistry, vasoactive peptide research, and receptor signaling. Sid spent half his life in Switzerland, after moving to the University of Bern in 1984. This article, written by his friends and colleagues who knew him and worked with him during different stages of his career, summarizes his life, his passions, and his achievements in biomedical research. It also includes personal memories relating to a dear friend and outstanding scientist whose intellectual curiosity, humility, and honesty will remain an example to us all.

The Second Tomoh Masaki Award (2013).

Professor Katsutoshi Goto, phD, a Japanese physio-pharmacologist born in 1943, is the recipient of the The Second Tomoh Masaki Award, a bi-annual prize presented on the occasion of the International Conferences on Endothelin to scientists for outstanding contributions and achievements in the field of endothelin research. The Second Tomoh Masaki Award was presented to Professor Goto at the Thirteenth International Conference on Endothelin held at Tokyo Campus of the University of Tsukuba, Tokyo, Japan, in September 2013 in recognition of his scientific contributions in the 1980s that ultimately allowed to identify and characterize the endothelin peptides. Goto's innovative work was quintessential in the discovery of endothelin which has led to the development of new therapies and new clinical applications in medicine and particularly pulmonary arterial hypertension. This article summarizes the career and the scientific achievements of Katsutoshi Goto, it includes statements of former students on his role as a mentor as well as the awardee's personal quotes, including a message to young endothelin researchers.

The First Tomoh Masaki Award (2011).

Professor Tomoh Masaki, a Japanese physician-scientist born in 1934, is particularly known for the discovery of endothelium-derived peptide endothelin and its receptors, among many other scientific achievements. In recognition of his work, the Tomoh Masaki Award was established in 2011 by the Endothelin International Advisory Board of The International Conferences on Endothelin as a biannual scientific prize in recognition of Masaki's innovative and ground-breaking work that has led to new clinical applications. The inaugural Tomoh Masaki Award was presented at The Twelfth International Conference on Endothelin held in Cambridge, UK, to one his former graduate students, Professor Masashi Yanagisawa as the first recipient of this award, who played an instrumental role in the discovery of endothelin at the University of Tsukuba, Japan. The article summarizes the scientific achievements of Masaki and the awardee, Masashi Yanagisawa, also including personal reflections of two of Masaki's former graduate students on their teacher as well as on the awardee of The First Tomoh Masaki Award 2011 and their work as scientists and their role as mentors.

Endothelin XII.

Following the initial description of endothelium-dependent vasoconstriction in the early 1980s, it has been exactly 25 years since efforts to identify the sequence of the endothelin gene and peptide began in May 1987, work which resulted in a landmark paper submitted to Nature in December 1987 and published on March 31, 1988. The paper opened an entirely new field of research, followed by the inception of the International Conferences of Endothelin, the first of which was organized by Sir John Vane as Chair and held as the "First William Harvey Workshop on Endothelin" in London, UK, in December of 1988. Endothelin receptor antagonism has now been firmly established for more than a decade as a new, orally active drug treatment for patients with pulmonary arterial hypertension. Since the discovery of endothelin, on average 1,000 papers per year have been published with more than 25,000 papers available today, many of them published in the conferences' Proceedings. The present issue of Life Sciences, Endothelin XII, represents a collection of papers of original research and invited lectures presented at the Twelfth International Conference on Endothelin held in Cambridge, UK, in September 2011.

Endothelin: 20 years from discovery to therapy.

Since its identification as an endothelial cell-derived vasoconstrictor peptide in 1988, endothelin-1, the predominant member of the endothelin peptide family, has received considerable interest in basic medical science and in clinical medicine, which is reflected by more than 20 000 scientific publications on endothelin research in the past 20 years. The story of endothelin is unique as the gene sequences of endothelin receptors and the first receptor antagonists became available within only 4 years of the identification of the peptide sequence. The first clinical study in patients with congestive heart failure was published only 3 years thereafter. Yet, despite convincing experimental evidence of a pathogenetic role for endothelin in development, cell function, and disease, many initial clinical studies on endothelin antagonism were negative. In many of these studies, study designs or patient selection were inadequate. Today, for diseases such as pulmonary hypertension, endothelin antagonist treatment has become reality in clinical medicine, and ongoing clinical studies are evaluating additional indications, such as renal disease and cancer. Twenty years after the discovery of endothelin, its inhibitors have finally arrived in the clinical arena and are now providing us with new options to treat disease and prolong the lives of patients. Possible future indications include resistant arterial hypertension, proteinuric renal disease, cancer, and connective tissue diseases.

Historical review: Endothelin.

Endothelin (ET) is a potent vasoconstrictive peptide that was isolated initially from the conditioned medium of cultured endothelial cells. In 1988, details of the isolation and identification, amino acid sequence, cDNA sequence and pharmacology of ET were published. Subsequently, ET isoforms, ET receptors and endothelin-converting enzyme (ECE) were cloned. Because ET was thought to be important in cardiovascular homeostasis, many investigators focused on the physiological and pathophysiological significance of ET. Accordingly, ET receptor antagonists and ECE inhibitors have been developed rapidly, mostly for the treatment of cardiovascular diseases. The field of molecular biology has provided valuable information about ET, including evidence that the ET system plays important roles in the early development of the neural crest and, thus, in the formation of organs. These results now present new avenues of ET research.